AR064215A1 - Proceso para obtener el r-enantiomero de salbutamol - Google Patents

Proceso para obtener el r-enantiomero de salbutamol

Info

Publication number
AR064215A1
AR064215A1 ARP070105517A ARP070105517A AR064215A1 AR 064215 A1 AR064215 A1 AR 064215A1 AR P070105517 A ARP070105517 A AR P070105517A AR P070105517 A ARP070105517 A AR P070105517A AR 064215 A1 AR064215 A1 AR 064215A1
Authority
AR
Argentina
Prior art keywords
salbutamol
obtaining
enantiomero
enantiomer
enantiomers
Prior art date
Application number
ARP070105517A
Other languages
English (en)
Inventor
Jozsef Balint
Florian Stolz
Original Assignee
Stirling Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stirling Products Ltd filed Critical Stirling Products Ltd
Publication of AR064215A1 publication Critical patent/AR064215A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

La presente se refiere a un proceso para obtener el R-enantiomero de salbutamol de una mezcla de los enantiomeros de salbutamol por cristalizacion de dicho R-enantiomero como su sal con R-ibuprofeno a partir de una solucion o lechada de una mezcla de los enantiomeros de salbutamol.
ARP070105517A 2006-12-11 2007-12-10 Proceso para obtener el r-enantiomero de salbutamol AR064215A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125842A EP1935872A1 (en) 2006-12-11 2006-12-11 Process for obtaining the R-enantiomer of salbutamol

Publications (1)

Publication Number Publication Date
AR064215A1 true AR064215A1 (es) 2009-03-18

Family

ID=38016561

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105517A AR064215A1 (es) 2006-12-11 2007-12-10 Proceso para obtener el r-enantiomero de salbutamol

Country Status (3)

Country Link
EP (1) EP1935872A1 (es)
AR (1) AR064215A1 (es)
WO (1) WO2008070909A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20111467A1 (it) * 2011-08-01 2013-02-02 Laboratorio Chimico Int Spa Procedimento per la preparazione di ivabradina e di suoi intermedi di sintesi
CN108947854B (zh) * 2018-06-30 2020-09-08 常州市阳光药业有限公司 重酒石酸间羟胺及其异构体的拆分方法
CN115286521B (zh) * 2022-07-11 2023-11-03 上海医药集团(本溪)北方药业有限公司 一种盐酸左沙丁胺醇的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1298494A (en) * 1970-06-17 1972-12-06 Allen & Hanburys Ltd Phenylethanolamine derivatives
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US5399765A (en) * 1994-05-23 1995-03-21 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
WO1999042460A1 (en) * 1998-02-20 1999-08-26 Fine Chemicals Corporation (Proprietary) Limited Process for the production of optically enriched (r)- or (s)-albuterol
GB0030171D0 (en) * 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol
EP1832572A1 (en) * 2006-03-08 2007-09-12 Stirling Products Limited Process for the enantiomeric enrichment of salbutamol and salbutamol precursors

Also Published As

Publication number Publication date
EP1935872A1 (en) 2008-06-25
WO2008070909A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
UY33317A (es) Nuevos derivados de pirazol
GT201300009A (es) Derivados de tetrahidro-pirido-pirimidina
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
SV2009003349A (es) Compuestos triciclicos, composiciones y procedimientos
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
EA201270216A1 (ru) Фармацевтический состав
EA201290416A1 (ru) Новые спиропиперидиновые соединения
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
AR062504A1 (es) Procedimientos para preparar acidos d,l-2hidroxi-4-alquiltiobutiricos
ECSP11011346A (es) 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3
BR112015015368A2 (pt) composições de absorventes de dejetos de animais revestidas debaixa densidade
CL2012002082A1 (es) Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios.
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
PE20140386A1 (es) Proceso para la produccion de fideos fritos
ECSP10010499A (es) Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida
CL2008002118A1 (es) Metodo para la produccion de un embrion equino de sexo seleccionado mediante la inyeccion intracitoplasmatica de esperma utilizando espermatozoides de equino seleccionados por sexo.
GT200700074A (es) Fungicidas
AR074545A1 (es) Proceso de preparacion de dihidroetorfina
BR112012009292A2 (pt) processo para preparação do composto, sal de potássio, solvato de acetona, forma cristalina, e, composto
EA201170721A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов рецептора хемокина
CO6470817A2 (es) Cristales de solvato novedosos

Legal Events

Date Code Title Description
FB Suspension of granting procedure